Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: back pain

IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results

Will Boggs MD  |  April 22, 2019

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) can safely switch from infliximab to the biosimilar CT-P13, though they may face a higher risk of clinical relapse, researchers from Spain report. Recent studies have demonstrated the effectiveness and safety of infliximab biosimilars in patients with IBD, but there are limited data about the effectiveness…

Filed under:Biologics/DMARDsDrug Updates Tagged with:biosimilar CT-P13inflammatory bowel disease (IBD)infliximabinfliximab biosimilar

Gout & Sexual Function

Lara C. Pullen, PhD  |  April 22, 2019

Pain, physical disability and joint deformity have been linked to sexual dysfunction. New research suggests gout may also significantly affect relationships and intimacy. The study found the physical effects of gout on intimacy, such as joint pain, were the top-ranked concern for gout patients…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:disabilityGoutintimacysex

Ethics Forum: Patient Safety at Home—What Are Our Legal & Ethical Responsibilities?

Sarah F. Keller, MD, & Marcy B. Bolster, MD  |  April 15, 2019

A 60-year-old woman with a six-month history of retroperitoneal fibrosis transfers her care to you. She initially presented with severe bilateral flank pain radiating to the abdomen and chest. A computerized tomography (CT) angiogram of the abdomen demonstrated an infrarenal abdominal aortic aneurysm surrounded by a thick inflammatory rind entangling the left renal vein and…

Filed under:EthicsLegal Updates Tagged with:abuseEthics Forumpatient safetyreporting

Valentyn Volkov / shutterstock.com

Did Shiitake Mushrooms Induce Immune-Mediated Necrotizing Myopathy?

Takeshi Yoshida, MD, Hiroaki Chikazawa, MD, Yoshitaka Kumon, MD, PhD, & Ichizo Nishino, MD, PhD  |  April 15, 2019

Idiopathic inflammatory myopathies are heterogenous, acquired immune-mediated muscle diseases. Over the past decade, immune-mediated necrotizing myopathy has been recognized as a subcategory of idiopathic inflammatory myopathy characterized by myofiber necrosis in the absence of prominent inflammatory cells.1 Autoantibodies against signal recognition particle (SRP) and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) are thought to be associated with the…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:2018 ACR/ARHP Annual Meetingcase reportDietmushroomsnecrotizing myopathyshiitake mushrooms

At Vasculitis Conference, Patients Share Hope, Humor & Hardships

Bryn Nelson, PhD  |  April 15, 2019

SEATTLE—At the first regional vasculitis patient conference ever held in the Pacific Northwest, a panoramic view of Mt. Rainier on a clear January morning set the tone for a day of optimistic talks about recent successes against the various forms of blood vessel inflammation. One attendee at the Jan. 12 conference, sponsored by the Vasculitis…

Filed under:Patient PerspectiveVasculitis Tagged with:vasculitis research

Addicted to Learning: Can We Teach as Well (& Enthrallingly!) as Fortnite?

Philip Seo, MD, MHS  |  April 15, 2019

My nephew is an addict. These words do not come easily to me, but I have come to accept them as true. In retrospect, I should have recognized the telltale signs: He stopped picking up the phone when I call. He disappears and then re-emerges hours later, seemingly having done nothing. He has lost interest…

Filed under:Education & TrainingOpinionRheuminationsSpeak Out Rheum Tagged with:augmented realitymassive open online course (MOOC)virtual reality

kenary820 / shutterstock.com

Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

Mary Choy, PharmD, BCGP, FASHP  |  April 15, 2019

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:abataceptadalimumabapremilastbrodalumabCertolizumab PegoletanerceptGolimumabinfliximabixekizumabPsoriatic ArthritisRheumatic Drugs at a GlancesecukinumabTofacitinibtreatment guidelinesustekinumab

Mirikizumab Promising for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  April 10, 2019

During a 16-week study, patients with plaque psoriasis taking mirikizumab experienced higher response rates and skin clearance compared with placebo…

Filed under:Biologics/DMARDsDrug Updates Tagged with:mirikizumabplaque psoriasisskin

SM04690 Promising for Knee OA

Michele B. Kaufman, PharmD, BCGP  |  March 27, 2019

SM04690, an intra-articular injection for knee OA, will soon enter phase 3 trials to assess its effects on pain, joint function and disease…

Filed under:Drug Updates Tagged with:disease-modifying osteoarthritis drug (DMOAD)joint injectionkneeKnee Osteoarthritis (OA)OsteoarthritisSM04690

FDA Approves Guselkumab Injector

Michele B. Kaufman, PharmD, BCGP  |  March 20, 2019

The FDA has approved a single-press, self-injection device for a 100-mg dose of guselkumab for adults with moderate to severe plaque psoriasis…

Filed under:Biologics/DMARDsDrug Updates

  • « Previous Page
  • 1
  • …
  • 84
  • 85
  • 86
  • 87
  • 88
  • …
  • 162
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences